The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hepatitis C Virus (HCV) Antiviral-Global Market Insights and Sales Trends 2024
Synopsis
Hepatitis C is a contagious liver disease caused due to hepatitis C virus. Hepatitis C damages and infects the liver. Hepatitis C is spread as the infected blood comes in contact with non-infected blood. Ranging in severity hepatitis C can cause acute and chronic hepatitis infection. Chronic hepatitis C is diagnosed by liver biopsy and blood tests. According to World Health Organization (WHO), globally 130 million to 150 million people are suffering from chronic hepatitis C. Hepatitis C is treated with antiviral drugs to inhibit the growth of virus and prevent liver damage. According to World Health Organization (WHO), 50% to 90% of people suffering from hepatitis C are treated with antiviral treatment.
The global Hepatitis C Virus (HCV) Antiviral market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatitis C Virus (HCV) Antiviral in various end use industries. The expanding demands from the Diagnostic Centers, Hospitals and Home Use,, are propelling Hepatitis C Virus (HCV) Antiviral market. HCV Antibody, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the HCV Viral Load segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatitis C Virus (HCV) Antiviral, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatitis C Virus (HCV) Antiviral market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatitis C Virus (HCV) Antiviral market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatitis C Virus (HCV) Antiviral sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatitis C Virus (HCV) Antiviral covered in this report include Roche Diagnostics, Abbott, Siemens, Qiagen, bioMérieux, Bio-Rad Laboratories, Meridian Bioscience, Vista Diagnostics and Biogate Laboratories, etc.
The global Hepatitis C Virus (HCV) Antiviral market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Diagnostics
Abbott
Siemens
Qiagen
bioMérieux
Bio-Rad Laboratories
Meridian Bioscience
Vista Diagnostics
Biogate Laboratories
J.Mitra & Co. Ltd
Siemens Medical
General Biologicals
Global Hepatitis C Virus (HCV) Antiviral market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatitis C Virus (HCV) Antiviral market, Segment by Type:
HCV Antibody
HCV Viral Load
HCV Genotyping
Global Hepatitis C Virus (HCV) Antiviral market, by Application
Diagnostic Centers
Hospitals
Home Use
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatitis C Virus (HCV) Antiviral companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hepatitis C is a contagious liver disease caused due to hepatitis C virus. Hepatitis C damages and infects the liver. Hepatitis C is spread as the infected blood comes in contact with non-infected blood. Ranging in severity hepatitis C can cause acute and chronic hepatitis infection. Chronic hepatitis C is diagnosed by liver biopsy and blood tests. According to World Health Organization (WHO), globally 130 million to 150 million people are suffering from chronic hepatitis C. Hepatitis C is treated with antiviral drugs to inhibit the growth of virus and prevent liver damage. According to World Health Organization (WHO), 50% to 90% of people suffering from hepatitis C are treated with antiviral treatment.
The global Hepatitis C Virus (HCV) Antiviral market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatitis C Virus (HCV) Antiviral in various end use industries. The expanding demands from the Diagnostic Centers, Hospitals and Home Use,, are propelling Hepatitis C Virus (HCV) Antiviral market. HCV Antibody, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the HCV Viral Load segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatitis C Virus (HCV) Antiviral, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatitis C Virus (HCV) Antiviral market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatitis C Virus (HCV) Antiviral market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatitis C Virus (HCV) Antiviral sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatitis C Virus (HCV) Antiviral covered in this report include Roche Diagnostics, Abbott, Siemens, Qiagen, bioMérieux, Bio-Rad Laboratories, Meridian Bioscience, Vista Diagnostics and Biogate Laboratories, etc.
The global Hepatitis C Virus (HCV) Antiviral market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Diagnostics
Abbott
Siemens
Qiagen
bioMérieux
Bio-Rad Laboratories
Meridian Bioscience
Vista Diagnostics
Biogate Laboratories
J.Mitra & Co. Ltd
Siemens Medical
General Biologicals
Global Hepatitis C Virus (HCV) Antiviral market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatitis C Virus (HCV) Antiviral market, Segment by Type:
HCV Antibody
HCV Viral Load
HCV Genotyping
Global Hepatitis C Virus (HCV) Antiviral market, by Application
Diagnostic Centers
Hospitals
Home Use
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatitis C Virus (HCV) Antiviral companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hepatitis C Virus (HCV) Antiviral
1.1 Hepatitis C Virus (HCV) Antiviral Market Overview
1.1.1 Hepatitis C Virus (HCV) Antiviral Product Scope
1.1.2 Hepatitis C Virus (HCV) Antiviral Market Status and Outlook
1.2 Global Hepatitis C Virus (HCV) Antiviral Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hepatitis C Virus (HCV) Antiviral Market Size by Region (2018-2029)
1.4 Global Hepatitis C Virus (HCV) Antiviral Historic Market Size by Region (2018-2023)
1.5 Global Hepatitis C Virus (HCV) Antiviral Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hepatitis C Virus (HCV) Antiviral Market Size (2018-2029)
1.6.1 North America Hepatitis C Virus (HCV) Antiviral Market Size (2018-2029)
1.6.2 Europe Hepatitis C Virus (HCV) Antiviral Market Size (2018-2029)
1.6.3 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Market Size (2018-2029)
1.6.4 Latin America Hepatitis C Virus (HCV) Antiviral Market Size (2018-2029)
1.6.5 Middle East & Africa Hepatitis C Virus (HCV) Antiviral Market Size (2018-2029)
2 Hepatitis C Virus (HCV) Antiviral Market by Type
2.1 Introduction
2.1.1 HCV Antibody
2.1.2 HCV Viral Load
2.1.3 HCV Genotyping
2.2 Global Hepatitis C Virus (HCV) Antiviral Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hepatitis C Virus (HCV) Antiviral Historic Market Size by Type (2018-2023)
2.2.2 Global Hepatitis C Virus (HCV) Antiviral Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Type (2018-2029)
3 Hepatitis C Virus (HCV) Antiviral Market Overview by Application
3.1 Introduction
3.1.1 Diagnostic Centers
3.1.2 Hospitals
3.1.3 Home Use
3.2 Global Hepatitis C Virus (HCV) Antiviral Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hepatitis C Virus (HCV) Antiviral Historic Market Size by Application (2018-2023)
3.2.2 Global Hepatitis C Virus (HCV) Antiviral Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hepatitis C Virus (HCV) Antiviral Revenue Breakdown by Application (2018-2029)
4 Hepatitis C Virus (HCV) Antiviral Competition Analysis by Players
4.1 Global Hepatitis C Virus (HCV) Antiviral Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatitis C Virus (HCV) Antiviral as of 2022)
4.3 Date of Key Players Enter into Hepatitis C Virus (HCV) Antiviral Market
4.4 Global Top Players Hepatitis C Virus (HCV) Antiviral Headquarters and Area Served
4.5 Key Players Hepatitis C Virus (HCV) Antiviral Product Solution and Service
4.6 Competitive Status
4.6.1 Hepatitis C Virus (HCV) Antiviral Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche Diagnostics
5.1.1 Roche Diagnostics Profile
5.1.2 Roche Diagnostics Main Business
5.1.3 Roche Diagnostics Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.1.4 Roche Diagnostics Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Diagnostics Recent Developments
5.2 Abbott
5.2.1 Abbott Profile
5.2.2 Abbott Main Business
5.2.3 Abbott Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.2.4 Abbott Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Recent Developments
5.3 Siemens
5.3.1 Siemens Profile
5.3.2 Siemens Main Business
5.3.3 Siemens Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.3.4 Siemens Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.3.5 Qiagen Recent Developments
5.4 Qiagen
5.4.1 Qiagen Profile
5.4.2 Qiagen Main Business
5.4.3 Qiagen Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.4.4 Qiagen Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.4.5 Qiagen Recent Developments
5.5 bioMérieux
5.5.1 bioMérieux Profile
5.5.2 bioMérieux Main Business
5.5.3 bioMérieux Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.5.4 bioMérieux Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.5.5 bioMérieux Recent Developments
5.6 Bio-Rad Laboratories
5.6.1 Bio-Rad Laboratories Profile
5.6.2 Bio-Rad Laboratories Main Business
5.6.3 Bio-Rad Laboratories Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.6.4 Bio-Rad Laboratories Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.6.5 Bio-Rad Laboratories Recent Developments
5.7 Meridian Bioscience
5.7.1 Meridian Bioscience Profile
5.7.2 Meridian Bioscience Main Business
5.7.3 Meridian Bioscience Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.7.4 Meridian Bioscience Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.7.5 Meridian Bioscience Recent Developments
5.8 Vista Diagnostics
5.8.1 Vista Diagnostics Profile
5.8.2 Vista Diagnostics Main Business
5.8.3 Vista Diagnostics Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.8.4 Vista Diagnostics Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.8.5 Vista Diagnostics Recent Developments
5.9 Biogate Laboratories
5.9.1 Biogate Laboratories Profile
5.9.2 Biogate Laboratories Main Business
5.9.3 Biogate Laboratories Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.9.4 Biogate Laboratories Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.9.5 Biogate Laboratories Recent Developments
5.10 J.Mitra & Co. Ltd
5.10.1 J.Mitra & Co. Ltd Profile
5.10.2 J.Mitra & Co. Ltd Main Business
5.10.3 J.Mitra & Co. Ltd Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.10.4 J.Mitra & Co. Ltd Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.10.5 J.Mitra & Co. Ltd Recent Developments
5.11 Siemens Medical
5.11.1 Siemens Medical Profile
5.11.2 Siemens Medical Main Business
5.11.3 Siemens Medical Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.11.4 Siemens Medical Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.11.5 Siemens Medical Recent Developments
5.12 General Biologicals
5.12.1 General Biologicals Profile
5.12.2 General Biologicals Main Business
5.12.3 General Biologicals Hepatitis C Virus (HCV) Antiviral Products, Services and Solutions
5.12.4 General Biologicals Hepatitis C Virus (HCV) Antiviral Revenue (US$ Million) & (2018-2023)
5.12.5 General Biologicals Recent Developments
6 North America
6.1 North America Hepatitis C Virus (HCV) Antiviral Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hepatitis C Virus (HCV) Antiviral Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis C Virus (HCV) Antiviral Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hepatitis C Virus (HCV) Antiviral Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis C Virus (HCV) Antiviral Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hepatitis C Virus (HCV) Antiviral Market Dynamics
11.1 Hepatitis C Virus (HCV) Antiviral Industry Trends
11.2 Hepatitis C Virus (HCV) Antiviral Market Drivers
11.3 Hepatitis C Virus (HCV) Antiviral Market Challenges
11.4 Hepatitis C Virus (HCV) Antiviral Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
